RCE Charts, page-362

Hope everyone has had a well earnt break and enjoyed the Christmas/new years period. I know RECCE put out a business update on the 16^th but thought I’d add some more information from the previous announcements for those who can be bothered reading it. My posts are few and far between these days so had some time today to update RCE information I’ve compiled.

It appears that RCE has gone “all in” with its COVID chips last year. Seeing we started 2020 with RECCE mainly directing its interests towards Sepsis, Burns, and a couple of other secondary infections (H. PYLORI and E. COLI) we how have one of our major pillars of development directed towards COVID. I feel it is an excellent opportunity and I’m happy that RCE has grabbed it with both hands.

a) It showcases R327 and R529 on a global platform that gets significant attention (we might not have gotten so much attention for just sepsis and burns) our share price seemed to move significantly after COVID announcements

b) We’re able to test our compounds against a virus (not just bacteria), that has the ability to have a major impact on a global scale.

c) This will put RCE in a strong position for any future strains or viruses that may happen in the future. “we’ve previously tested R327/R529 on COVID19 and had encouraging/successful results… this new virus has a similar RNA profile… bang! Ahead from the start.

Yes COVID isn’t our inceptual reason for development but it never hurt to have another iron in the fire so to speak. I firmly believe we will get more from R327 on burns and sepsis trials but I think this pillar of the business is worth pursuing against COVID.

Murdoch Children’s Research Institute - RECCE® 435 Against Helicobacterpylori stomach bacteria. Recce and MCRI will work together on the oral antibiotic dosing program with a particular focus on optimal dosing and the effect of RECCE® 435. The agreement is in place until 31 December 2022; however, the Company anticipates completion in approximately 12 months, at which time it will pursue a human clinical trial.

CMAX Clinical Trial Facility ForPhase I Study of Synthetic Antibiotic RECCE® 327. The Phase I clinical trial is arandomised, double blind, placebo-controlled single ascending dose study of 48healthy adult subjects. The study seeks to evaluate the safety, tolerability,pharmacokinetics and pharmacodynamic profile of RECCE® 327 following intravenousadministration. Completion Q4 2020. Patient screening Q1 2021

RECCE® 327(R327) &RECCE® 529 (R529) (US Trials) compounds have shownconcentration-dependent reductions in the SARS-CoV-2. RECCE® 327 and RECCE® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection. The results, in both R327 and R529, demonstrated a positive reduction in COVID-19 viral load compared to the placebo group. A gold-standard ferret COVID-19 study is underway in the United States seeking to build upon this method of administration, including higher dose concentrations and two other forms of administration, only possible in larger species. These data are expected in early 2021.

RECCE® Compounds tested by CSIRO/Doherty Institute inPriority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program (R327) Antiviral SARS-CoV-2 Screening Program showing RECCE® 327 (R327) had encouraging inhibition of the SARS-CoV-2 virus. Half maximal inhibitory concentration (IC50) of 109.8 ppm was identified in the screen. (Half-maximal inhibitory concentration (IC50) is the most widely used andinformative measure of a drug's efficacy. It indicates how much drug is neededto inhibit a biological process by half, thus providing a measure of potency ofan antagonist drug in pharmacological research)

Preliminary indications of potential toxicity were observed in the 2 highest concentration tested (4000 ppm and 2000 ppm) R327 shows encouraging results at 109.8ppm. toxic levels observed at 2000/4000ppm. Stage 1b (confirmation and cytotoxicity) .is expected to have already started. I imagine we will get some results in January or February.(Cytotoxicity is an in vitro test to determine whether themedical device will cause any cell death due to leaching of toxic substances orfrom direct contact)

Topical Phase I/II Human Clinical Trial Submission

Topical Phase I/II human clinical study is on track and progressing well. The Company recently announced it has received Human Research Ethics Approval for its Phase I/II human topical clinical trial in infected burn wounds and is closely working with South Metropolitan Health Service (Department of WA Health) on operational specifics with first patient treatment anticipated Q1 2021. Over 14 days, 10 patients will receive RECCE® 327 dailywhile a further 20 receive treatment 3 times per week

$23 million AUD in the bank. Market cap 183M @$1.055. 173.63 million shares on issue.

Looking forward to 2021 with the RCE train